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ABSTRACT 
Amblyopia, defined as poor vision due to abnormal visual experience early in life, affects 
approximately three percent of the population and carries a projected lifetime risk of vision 
loss of at least 1.2%.  The presence of amblyopia or its risk factors, mainly strabismus or 
refractive error, have been primary conditions targeted in childhood vision screenings.  The 
continued support for such screenings requires evidence-based understanding of the 
prevalence and natural history of amblyopia and its predisposing conditions, and proof that 
treatment is effective in the long term with minimal negative impact on the patient and their 
family.     
This review summarises recent research relevant to the clinical understanding of 
amblyopia, including prevalence data, risk factors, the functional impact of amblyopia and 
optimum treatment regimes and their justification from a visual and life skills perspective.  
Collectively, these studies indicate that treatment for amblyopia is effective as it reduces 
overall prevalence and severity of vision loss.  Correction of refractive error alone has been 
shown to significantly reduce amblyopia and lessor amounts of occlusion can be just as 
effective as greater amounts.  Occlusion or penalisation in amblyopia treatment can create 
negative changes in behaviour in children impact on family life and these factors should be 
considered in prescribing treatment, particularly because of their influence on compliance 
with prescribed treatment. Treatment trials regarding the maximum age at which amblyopia 
treatment can still be effective and the importance of near activities during occlusion are 
ongoing.  This review highlights the expansion of current knowledge regarding amblyopia 
and current treatment of amblyopic patients and aims to keep clinicians abreast of this 
knowledge.  
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Introduction 
Amblyopia has been defined as a unilateral or bilateral decrease of visual acuity caused by 
deprivation of pattern vision or abnormal binocular interaction, for which no cause can be 
detected by physical examination of the eye and which can in some cases be reversed by 
therapeutic measures(1).  Amblyopia is a disorder of development of the visual system that 
can present with varying levels of severity and usually affects one eye only, although the 
non-amblyopic eye often has an array of small but measurable deficits(2).  There is no 
obvious ocular pathology underlying the reduced visual acuity but rather, there is some 
pre-disposing condition that influences the development of visual acuity after birth.  The 
most common pre-disposing conditions for amblyopia are strabismus (causing disruption of 
binocular vision development), refractive error (particularly anisometropia or hyperopia), or, 
more rarely, media opacification causing reduction in image quality (such as congenital 
cataracts).  The earlier in post-natal visual experience the predisposing condition presents, 
the greater the potential impact on vision.  In addition, the longer the duration of abnormal 
visual experience the more profound the level of amblyopia. 
 
Amblyopia is usually classified according to the presenting visual condition believed to 
have caused the impaired visual development.  An example of this classification is that 
used by Attebo et al(3), where amblyopia was identified in their population cohort as (1) 
anisometropic if there was a difference in the sphere or cylinder between the two eyes of 
one dioptre or more and no strabismus was present; (2) strabismic if heterotropia or micro-
squint was present without anisometropia or high refractive error; (3) mixed if 
anisometropic amblyopia and strabismic amblyopia co-existed or (4) stimulus deprivation if 
there was some obstruction to vision during the sensitive period of visual development (this 
included high refractive errors).(3)    
 
Clinically, amblyopia is usually defined by one or more lines difference in visual acuity 
between the eyes(4), however, other monocular visual functions are also affected, 
including grating acuity, vernier acuity and contrast sensitivity.  Amblyopic eyes can also 
have defective accommodation and can display oculo-motor deficits including unsteady 
fixation and inaccurate tracking; the tracking of the non-amblyopic eye can also be less 
accurate than in age-matched controls(5).  Binocular vision adaptations may be present 
including suppression, eccentric fixation or abnormal retinal correspondence(6,7). Deficits 
in stereopsis are present under normal binocular conditions and may represent the main 
functional difference between patients with amblyopia and those without.  Most strabismic 
amblyopes lack any measurable stereopsis even if visual acuity has recovered, while many 
anisometropic amblyopes have some residual stereopsis that may be as good as the 
resolution of the amblyopic eye permits(7).     
 
The different patterns of monocular and binocular visual loss seen in strabismic versus 
anisometropic amblyopia suggests the existence of two distinct developmental 
anomalies(6-8).  A recent review explores the literature pertaining to the physiological locus 
of amblyopia and indicates that the specific neurophysiologic mechanism underlying 
amblyopia may be inter-ocular image conflict that reduces inter-ocular summation while 
promoting inter-ocular inhibition.  This is interpreted as reducing the effectiveness of 
excitatory neural connection in the cortex while sparing inhibitory connections(2).   More 
recent psychophysical studies have suggested that the visual dysfunction in amblyopia 
may begin at the retina(9).      
 
During the past 20 years, different critical periods have been demonstrated for different 
visual functions during the development of the visual system. Visual functions processed at 
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higher anatomical levels within the system have a later critical period than functions 
processed at lower levels. This general principle suggests that treatments for amblyopia  
should follow a logical sequence, with treatment for each visual function starting before its 
critical period is over. However, critical periods for some visual functions, such as 
stereopsis, have not yet been completely defined, and the optimal treatment has, therefore, 
not been fully determined(10).  
 
The prognosis for obtaining and maintaining essentially normal vision in an amblyopic eye 
depends on many factors, including the age of the patient at detection, the cause and 
severity of amblyopia, the presence of complicating factors, the interval between the onset 
of amblyopia and the beginning of treatment and compliance with treatment.  Treatment 
success may also be a function of the duration of abnormal visual experience under the 
influence of the predisposing amblyogenic condition, rather than simply the age at 
treatment.   
 
The mainstay of amblyopia treatment is management of the underlying amblyogenic 
condition, thereby increasing visual stimulation of the amblyopic eye and removal of 
barriers leading to abnormal visual input to the brain. This is followed by occlusion or 
penalisation of the dominant eye that aims to enhance cortical processing of visual input 
from the amblyopic eye by temporarily limiting cortical input from the dominant eye.    
Penalisation may take the form of image degradation by instillation of atropine drops, 
refractive blur or translucent patching of the better eye.   
 
Pre-school vision screenings have for many years aimed to provide a safety net by 
identifying children with amblyopia risk factors whilst they are still within the critical period 
of treatment efficacy (traditionally believed to be up to eight years of age).  Refractive error 
and non-cosmetically obvious strabismus have been targeted conditions of screenings, 
with the premise that the amblyopia risk factors of media opacity or large angle strabismus 
would have been identified by a parent or primary health provider during infant or early 
child health assessments.  A 1997 review of literature into the conditions targeted in pre-
school vision screening, namely refractive error, amblyopia and non-cosmetically obvious 
strabismus, concluded that there is a lack of good quality research into the natural history 
of these conditions, the disability associated with them and the efficacy of available 
treatments(11).  Following its publication, the review’s conclusions were much debated in 
the ophthalmological literature, with criticism that recommendations made by the review 
lacked objectivity and that a lack of adequate data on the effectiveness of amblyopia 
treatment may result in a premature disassembly of preschool vision screening 
programmes(12-14).    A positive outcome of the publication is that the randomised 
controlled trials that it called for have now appeared in the literature. 
 
The aim of this review is to present recent research regarding the prevalence and natural 
history of amblyopia, the efficacy of treatment and its impact on the patient.  In doing so, a 
balanced representation of these studies is provided that can contribute to the clinical 
understanding of optimum treatment regimes for amblyopia and their justification relative to 
a whole of life consideration of a patient’s needs.  
 
Prevalence 
The reported prevalence of amblyopia depends upon both the study population and the 
definition of amblyopia used.  Adult population studies have reported the prevalence of 
amblyopia to range from 1% to 5%,(3,4) however, population selection bias may influence 
prevalence rates.  For example, studies from clinical ophthalmic populations are not 
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representative of the general population and typically present with higher prevalence rates 
of amblyopia.  Recent Australian adult population-based cohort studies that aimed to avoid 
such bias reported the prevalence of unilateral amblyopia to be 3.06% (n=4721)(15)  and 
3.2% (n=3654) (3) when amblyopia was defined as best corrected VA of 6/9 or worse.   
 
The pre-disposing cause for amblyopia has been shown to vary between studies 
dependent upon the characteristics of the study sample, particularly how amblyopia was 
defined. In the unselected adult population study of Attebo(3), where amblyopia was 
defined as best corrected VA of 6/9 or worse, the main cause was anisometropia (50%), 
with strabismus being the pre-disposing condition in 19%, mixed (both strabismus and 
anisometropia) in 27% and visual deprivation in 4%.   While in a cohort of children with 
moderate amblyopia (amblyopic VA was 6/12 to 6/30; n=409; mean age 5.3 years) the 
causes were found to be strabismus in 38%, anisometropia in 37% and mixed in 24%(16) 
and in children with severe amblyopia (amblyopic VA 6/30 to 6/120; n=175; mean age 4.8 
years) the causes were found to be anisometropia in 34%, strabismus in 27% and mixed in 
38%(17).  
 
Recent data regarding the prevalence of amblyopia at 7.5 years of age is provided by the 
Avon longitudinal study of parents and children (ALSPAC), which is a UK population birth 
cohort study(18).  Of 6,081 children, 16.7% had attended preschool vision screening (age 
3-4 years) and all the children had been offered vision screening in the school reception 
class (age 4-5 years). The prevalence of amblyopia was significantly lower in those 
children who had received preschool screening compared with those who had not (1.1% v 
2.0%, p=0.05).  This finding confirms that of a large Israeli study which found a 1% 
prevalence of amblyopia in 8 year old children previously screened and treated for 
amblyopia compared with 2.6% in a matched population that had not received 
treatment(19).  
 
In summary, the most recent population studies of amblyopia indicate a prevalence of 
approximately 3% in untreated childhood and current adult populations.  With detection and 
treatment of the amblyogenic condition by five years of age, the prevalence of clinically 
significant amblyopia reduces to around 2%.  With detection and treatment before three 
years of age, the prevalence of clinically significant amblyopia reduces to around 1%.  The 
results of the ALSPAC and Israeli childhood amblyopia studies suggest that early 
screening for and treatment of conditions that pre-dispose amblyopia reduce the 
prevalence of amblyopia in school-aged children. 
 
TABLE 1: Reported Prevalence of amblyopia in selected populations 
 
Risk Factors for Amblyopia 
Amblyopia is more than four times as common in infants who are premature, small for 
gestational dates or who have a first degree relative with amblyopia.  In infants with neuro-
developmental delay the prevalence of amblyopia is six times greater than in healthy, full-
term infants(20,21).  Patients at greatest risk for amblyopia are infants who experience 
early stimulus deprivation.  Visual deprivation prior to three months of age need not be 
prolonged to cause amblyopia and is highly correlated with later development of sensory 
nystagmus in bilateral cases and strabismus in both monocular and bilateral cases. 
 
In strabismus, the diplopia caused by the misalignment can lead to binocular rivalry and 
suppression of input from the non-dominant eye at the level of the visual cortex.   Infantile 
esotropia (i.e. congenital esotropia) generally presents before six months of age when the 
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developing visual system can be most at risk for amblyopia.  If not corrected early, the 
resultant amblyopia can be profound and difficult to reverse.  In patients who have had 
early surgery with an outcome of good visual acuity in both eyes, very poor stereopsis can 
still result due to the early disruption of binocular vision(7). 
 
Refractive error represents a risk for developing amblyopia, either due to creation of 
dissimilar images in anisometropic amblyopia, or as a driving factor for accommodative 
esotropia.  Children identified at screening as at risk for amblyopia due to hyperopia > or = 
3.5 D in any meridian were 13 times more likely to become strabismic and six times more 
likely to show measurable acuity deficits by four years compared with controls(22).  
Wearing a partial spectacle correction reduced these risk ratios to 4:1 and 2.5:1 
respectively and did not interfere with the process of emmetropisation (the reduction in 
magnitude of refractive error seen in children aged between 9 months and 4 years)(22). 
 
Most studies report best-to-worst ranking  for visual acuity at initial visit and outcome at the 
end of treatment as anisometropic (best), strabismic and combined 
strabismic/anisometropic amblyopia (worst) and the same ranking for least-to-most post-
treatment deterioration in long-term follow-up(2).   Complicating the interpretation of 
expected treatment outcomes is the inter-relationship between strabismus and amblyopia 
as each can be causal of the other.  Similarly, strabismus and anisometropia commonly co-
exist and it may be difficult to determine which is the primary condition. 
 
Natural History 
The studies of early treatment intervention regimes allow better understanding of the 
natural history of amblyopia.  The finding that those populations that undergo early 
intervention and treatment have lower prevalence of amblyopia that those that do not, 
implies that amblyopia does not improve of its own accord(18,19). 
 
Further evidence that treatment is necessary for optimum visual acuity outcomes is 
provided by the randomised controlled treatment trial by Clarke et al (23) where best 
corrected acuity was compared in those who had received one year of treatment with those 
who had not.  177 children aged 3-5 years, identified at pre-school vision screening as 
having monocular reduction in VA worse than 6/9, were randomly assigned to either a no 
treatment group, were treated with glasses alone or with glasses and patch occlusion.  Of 
the total sample, 173 (98%) had a significant refractive error, 127 (72%) of whom had 
anisometropia.  Children in either treatment group had better visual acuity at follow up than 
children who received no treatment (mean improvement 0.11 logMAR - just over one line of 
acuity).  The effects of treatment depended on initial acuity, with those children with initial 
acuities in the range of 6/18 to 6/36 improving on average 0.20 logMAR following 
treatment.  After twelve months the no treatment group then received the treatment, with 
subsequent improvement in visual acuity and stereopsis equal to that of patients who had 
initially received treatment(24).  This latter finding indicates that in a group of mainly 
refractive amblyopes, treatment does improve final vision, however, delay of treatment until 
five years of age does not influence the final visual outcome.   
 
To investigate the natural history of amblyopia without treatment, Simons and Preslan (25) 
reported longitudinal data on the course of amblyopia in a group of 18 children who were 
identified as amblyopic in a screening study but who either did not receive or did not 
comply with recommended treatment and then were retested a year later.  Improvement in 
visual acuity in the amblyopic eye was reported in one child, in seven children visual acuity 
had deteriorated in the amblyopic eye, and the rest of the group showed no change.  
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These authors also reanalysed data from three other studies (26-28) and found that the 
visual acuity outcomes for those patients who had been compliant with treatment were 
significantly better than those who were not. They concluded that untreated children with 
either amblyopia or its risk factors are likely, at best, to show no improvement in the 
amblyopic eye if untreated and, in many cases, develop amblyopia if not treated.     
 
Recent randomised controlled treatment trials, together with reviews of patients who have 
not been compliant with treatment, indicate that the natural history of amblyopia is not that 
of spontaneous recovery.  Intervention is required to maximise potential visual acuity in the 
affected eye.  The age at which that intervention will still be effective has not been 
confirmed and is the subject of on-going studies(29). 
 
Disability Associated with Amblyopia 
Amblyopia is often considered to be a childhood condition as this is when it is most often 
diagnosed and treated.  Thus clinicians need to know which life skills relevant to a child 
may be affected if amblyopia is left untreated and be aware of any functional difficulties that 
a child may experience during and following treatment.   
 
At least 64% of parents of amblyopic children have been reported to express concerns 
regarding disability associated with amblyopia. Parents of children with early diagnosis 
(before age five years) were more likely to consider amblyopia a very serious problem 
(58% versus 39%), while parents of children with late diagnoses more frequently reported 
that their child had problems attributed to amblyopia (80% versus 64%).  Reported 
problems were typically those of school performance rather than related to social or athletic 
activities(30).   
 
These findings contradict those of Snowdon and Stewart-Brown (31) who conducted semi-
structured interviews on a small number of parents of children with amblyopia (n=11).  The 
authors concluded that these parents did not regard amblyopia as a disabling condition, 
with little impact on career choice or motor function.  However, they report that adults with 
amblyopia found certain aspects of driving problematic, with driving at night being 
particularly identified as difficult.  This study also reports that practitioners who treat 
amblyopia generally agree that amblyopia may limit career choices due to visual standards 
and that there is a need to promote maximum vision in each eye to decrease lifetime risk of 
visual impairment.  Their overall conclusions were that treatment of amblyopia by patching 
may result in more disabling outcomes than the condition itself; however, the small sample 
population limits the relevance of this study, as does the lack of information regarding 
visual acuity, stereopsis or aetiology and lack of data from a control group.   
 
Potential disability in amblyopia has also been investigated by assessing the risk of visual 
impairment attributable to loss of vision in the non-amblyopic eye.  The projected lifetime 
risk of vision loss for an individual with amblyopia has been found to be at least 1.2%.  Rahi 
et al(32) found that of 370 individuals with amblyopic VA of worse than 6/12 who had newly 
acquired vision loss in their non-amblyopic eye, 104 (28%) had socially significant visual 
impairment (VA between 6/12 and 6/18), 180 (49%) had visual impairment (VA between 
6/18 and 6/60) and 86 (23%) had severe visual impairment or blindness (VA less than 
6/60).  Only 36 (35%) of 102 people previously in paid employment were able to continue 
to work.  The authors argue that the risk of visual loss in the non-amblyopic eye and its 
consequences are greater than that previously assumed.   
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The patient’s perception of quality of life associated with unilateral versus bilateral good 
vision has been calculated by utility analysis, which is a variation of cost-effectiveness 
analysis incorporating the value (improvement in the length of quality of life, quality of life or 
life) conferred by an intervention against the cost associated with that intervention.  Good 
vision in both eyes provides a substantial improvement in utility value as compared with 
good vision in only one eye.  Patient feedback indicates that the psychological stress of 
having only one good seeing eye on which to rely upon and the apprehension induced by 
knowing that many eye diseases eventually affect both eyes is likely to play a major role in 
decreasing an individual’s quality of life(33).  When specifically modelled in amblyopia, the 
cost of amblyopia treatment combined with the increase in utility value created by 
restoration of better vision in the second eye indicates that amblyopia treatment is highly 
cost-effective from the third-party insurer viewpoint and contributes to the earning power of 
affected individuals(34). 
 
In summary, the potential visual disability due to loss of visual function of the non-
amblyopic eye can be calculated and is an argument for amblyopia treatment to maximise 
visual potential in each eye.  The benefit of improvement in visual capacity of the 
amblyopic eye can also be quantified by quality of life scores and can result in positive 
cost-analysis of treatment.  Whilst parental concern regarding their amblyopic child’s 
performance has been reported, specific research into which life skills may be impaired by 
amblyopia is limited to studies with only small sample sizes.     
Impact of Amblyopia on Visuomotor Skills 
Reduced stereopsis is the most common visual deficit associated with amblyopia.  Whilst 
much is known about the visual basis of stereopsis, the functional significance of reduced 
stereopsis has rarely been reported (35).  Studies that have investigated this issue have 
compared performance under monocular and binocular conditions(36,37), generally 
concluding that individuals with binocular vision have advantages in situations requiring 
spatial certainty when compared with monocular individuals(36), that binocular vision 
facilitates control of manipulation, reaching and balance(37) and that people with no 
stereopsis have difficulty performing tasks which rely on three dimensional visual clues(38).  
However, there are individuals who have better manual dexterity than can be predicted by 
stereoacuity measures alone(38).  
 
Parents of strabismic children whose eyes have been aligned surgically have reported that 
the child’s visuomotor skills have suddenly and vastly improved following surgery(1).  This 
observation was confirmed in a study that assessed infants’ performance on the Bayley 
Scale of Infant Development both before and after surgery for infantile esotropia.  Following 
surgery, 35% of children showed an increase in performance on tests of fine motor skills 
and 41% of children recorded an improvement in visually directed reaching and grasping.  
The greatest post-operative improvement was found in the subtest item that involves depth 
perception, where the child is required to identify a depression in a piece of wood without 
monocular clues (such as a difference in colour) (39).   
 
Of relevance to the question of how the restoration of binocular vision affects visuomotor 
skills, is the study of Ross et al (40) who tested for developmental delay in patients who 
had undergone treatment for retinoblastoma;  75% of the test group was monocular 
resulting from enucleation.   Whilst on average the children’s mental and motor ability 
scores were in the normal range, approximately 40% of the mainly monocular test group 
was referred for delays of visuo-motor development, including tasks that require eye-hand 
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coordination and depth perception, such as placing pegs into holes or putting puzzle pieces 
into foam boards.   
 
There is little published evidence regarding the relationship between stereopsis and motor 
skills in children with amblyopia.  An exception is that of Hrisos et al(41), who found that 
stereoacuity, independent of visual acuity, significantly influenced performance on tasks 
requiring fine visuo-motor control (bead threading task) in non-strabismic amblyopic pre-
school children with reduced acuity in one eye (6/9 to 6/60).  No significant differences 
were found between these children and age-matched controls on other items in the battery 
that measured visuo-motor integration, visual spatial processing, visual attention, and 
gross visuo-motor skills.    
 
In summary, while it is assumed that reduced depth perception results in poor fine motor 
skill performance, there is little published evidence to support these assertions.  Fine motor 
skill performance underlies many tasks of importance to pre-school and school-aged 
children, such as hand-writing and scissor skills.  Exploring the relationship between 
reduced stereopsis and poor ocular-motor control, common findings in children with 
amblyopia, and fine motor skills is necessary to determine how amblyopia may impact 
upon early educational development. 
 
Impact of Amblyopia on Psychosocial development 
The psychosocial implications of strabismus and amblyopia on an individual’s quality of life 
have gained recent attention in the literature.  Anecdotal references to the undesirable 
cosmetic appearance associated with an obvious strabismus have more recently been 
superseded by studies looking at the effect of strabismus and amblyopia on an individual’s 
self-esteem, interpersonal relationships and employability. 
 
In their review paper, Tolchin and Lederman (8) discuss ways in which congenital or 
infantile esotropia may affect the parent-child relationship during the first years of life, and 
how this, in turn, can have profound psychological consequences for the developing child.  
They concluded that there was evidence in the literature that the child’s appearance plays 
a profound role in the developing parent-child relationship and that the cosmetically 
obvious ocular misalignment with infantile esotropia is one barrier to the eye contact 
necessary for a proper relationship to take place. 
 
Eustis and Smith (42) found that 41% of parents whose children underwent strabismus 
surgery believed that their child’s psychological development or personal self-esteem was 
adversely affected by strabismus and 17% of parents believed that the cosmetic stigma of 
strabismus was the single most important problem for their child.  This parental belief was 
confirmed by Satterfield et al (43), who found that patients with strabismus reported 
difficulty with self-image, securing employment, interpersonal relationships, school, work 
and sports.  The difficulties experienced continued and intensified in the teenage and adult 
years where patients with strabismus demonstrated higher levels of stress compared to 
age and sex-matched controls.  This contrasts with the findings of Gray et al (44) who 
found that individuals seeking surgery for strabismus, that they considered cosmetically 
unacceptable, were not in general “neurotic” or experiencing high levels of social anxiety.  
Patients who underwent surgery for longstanding horizontal strabismus perceived that their 
psychosocial functions had improved post surgery, but felt that other people would still rate 
them less highly than they rated themselves(45). 
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Satterfield et al’s finding regarding difficulty securing employment was confirmed by two 
more recent studies which demonstrated that cosmetically obvious strabismus creates a 
significant negative social prejudice in patients which can significantly reduce an 
applicant’s ability to obtain employment (46,47).   
 
Patients with amblyopia but without strabismus reported that amblyopia interfered with 
school, work to some degree, and felt it affected their lifestyle(48).  Sixty percent were 
concerned by associated teasing or ridicule, with the majority of patients reporting some 
concern that amblyopia had an effect on self-image.  Whilst most patients reported that 
their monocular condition had not affected their job choices, half reported that being 
monocular affected their lifestyle.  Amblyopic subjects were also found to experience more 
distress in the areas of somatization, obsession-compulsion, interpersonal sensitivity, 
anxiety and depression than control subjects.  
 
While these studies provide an understanding of the adults’ perspective on the psycho-
social impact of amblyopia, further research is needed to investigate the impact of 
treatment for amblyopia or any disability associated with amblyopia on the psychological 
well-being of the child.   
  
AMBLYOPIA TREATMENT  
The treatment of amblyopia generally involves correction of the underlying pre-disposing 
condition followed by a period of deprivation of the dominant eye to promote normal visual 
experiences for the amblyopic eye.  Refractive correction is also required for strabismic 
patients with accommodative esotropia and patients with anisometropia.  The results of 
randomised controlled treatment trials for various aspects of amblyopia treatment are now 
available.  The younger the child is when treatment commences, the more rapid the 
response to treatment and the better the visual outcome.  In strabismic amblyopia the rate 
of improvement in amblyopia treated with full time occlusion fell steadily from over 90% at 
age 28 to 33 months to near zero when therapy was initiated at age 12 years(49).  
Individual patients, however, may achieve improved vision after the age of 10 years, with 
reports of improvement with treatment or after loss of the non-amblyopic eye even into 
adulthood(50). 
 
Refractive correction  
Correction of any underlying refractive error has long been established to be critical in 
amblyopia treatment(6).  However, it is only more recently that the extent to which the 
correction of refractive error alone might reduce amblyopia has been specifically 
explored(51,52).  Correction of refractive error alone in newly diagnosed amblyopic 
children (n=65; mean age 5.1 years) for a period of 18 weeks resulted in significant 
improvement in amblyopic visual acuity (mean improvement of 0.24 logMAR).  This 
improvement did not significantly differ as a function of amblyopia type or age of the 
patient(52).  This has lead to the conclusion that refractive adaptation is a distinct 
component of amblyopia treatment and that the beneficial effects of refractive adaptation 
need to be fully identified.  Allowing refractive adaptation prior to commencement of 
occlusion or penalisation therapy may have significant benefits.   The consequences of 
these findings for clinical practice are that following a period of refractive correction, 
children can start occlusion with improved visual acuity, possibly enhancing compliance, 
and in some cases unnecessary patching can be avoided(53).  
 
Correction of abnormal ocular alignment or opacity 
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It has been conservatively estimated that 17% of patients with amblyopia will undergo 
alignment surgery, 1.5% require cataract extraction and 1.5% require ptosis surgery(34).  
Whilst no large population-based study addressing the distribution and incidence of each 
type of strabismic amblyopia is available, a cost-utility analysis study has assumed from 
case series and anecdotal experience that approximately 60-75% of strabismic amblyopes 
are accommodative, with 60% of accommodative esotropes not fully correctable with 
spectacles and requiring surgery for ocular alignment(34).  The subgroup of strabismus 
patients with amblyopia who will undergo alignment surgery was estimated to be from 48% 
to 62% of all amblyopic patients who have strabismus.    
 
Occlusion and Penalisation 
The mainstay of treatment for the last quarter of a century has been occlusion of the better 
eye by an opaque patch. However, therapeutic regimes have lacked standardisation with 
the length of patching ranging from a few minutes a day to all waking hours and in some 
cases treatment may last many months. Recent studies that have investigated the relative 
merits of occlusion and atropine penalisation have commented on the considerable 
variation in treatment practices with regard to the number of hours of initial patching 
prescribed(54).  Whilst the number of hours prescribed had no relationship to patient age, it 
was found to be related to the acuity in the amblyopic eye (i.e. depth of amblyopia).  On 
average optometrists prescribed fewer hours of patching than ophthalmologists(54).  
 
Recent randomised controlled treatment trials have aimed to evaluate different treatment 
modalities for different levels of amblyopia.  Trials of occlusion treatment by the Pediatric 
Eye Disease Investigator Group (PEDIG) have concluded that both atropine penalisation 
and patch occlusion are effective treatments for moderate amblyopia in children aged three 
to seven years(55); that when patching is prescribed, two hours of daily patching is as 
effective for moderate amblyopia as six hours; and that for severe amblyopia, six hours of 
daily patching is just as effective as full-time patching(17). Weekend atropine provides an 
improvement in VA of a magnitude similar to that of the improvement provided by daily 
atropine in treating moderate amblyopia in children three to seven years old(56). 
 
When occlusion is objectively (electronically) monitored, the overall compliance with 
prescribed patching treatment has been found to be 48% with considerable variation within 
and between participants.  When six hours of patching per day was prescribed, on average 
the patient actually received a “dose” of 2.8 hours, with only fourteen percent actually 
patching to an amount within 30 minutes of that prescribed(53).  Dose-response functions 
have been developed based upon how much patching the patient actually received and the 
initial and final visual acuity.  From these dose response functions, the relationship 
between visual acuity and treatment dose has been found to be monotonic, with 82% of the 
improvement in VA being achieved by six weeks of patching, but with some further 
improvement up to 12 weeks.  Dose rates of two to six hours per day resulted in the same 
final outcomes, although those with a high dose rate achieved a successful outcome more 
rapidly(53).   
 
Whilst randomised controlled treatment trials have shown occlusion and penalisation 
therapy to be successful in treating amblyopia in children younger than seven years, the 
question of the upper age limit of successfully treating amblyopia has still not been fully 
addressed.  A pilot study of treatment in children aged 10 to 18 years has indicated that 
visual acuity can be improved in older children and adolescents.  Randomised controlled 
trials are underway to determine if there is an upper age limit for which amblyopia 
treatment can still be successful(29).   
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Passive versus active treatment 
While a preliminary study found an average of one logMAR line extra improvement when 
the patient performed near activities during occlusion or penalisation(57), the benefits of 
active versus passive therapy during occlusion are yet to be confirmed by randomised 
controlled treatment trials.  Despite this the protocols of PEDIG has been to prescribe at 
least one hour of near visual activities during patching, for example, hand-eye activities, 
computer or Internet, reading, homework, accommodative tasks.   Preliminary studies have 
indicated that the use of video display treatment and biofeedback can achieve 
improvements in amblyopic visual acuity in adults, however, nearly all of the improvement 
in visual acuity achieved with treatment appears to regress if patients are followed up over 
an 18 month period(2).   Although patching alone may be sufficient for improvement of 
visual acuity, it has been suggested that binocular performance is significantly better when 
vision therapy is included in the treatment regimen(58). 
 
Medical Treatment 
Attempts have been made to involve catecholamines in amblyopia treatment, as they 
appear to extend or reactivate the visual system’s “sensitive period” of neural plasticity.  
Both levodopa(59-61) and CDP-choline which stimulate availability of a variety of 
neurotransmitters and modulators, including dopamine, have been used.    Whilst 
improvements in visual function in amblyopic eyes have been reported in both children and 
adults, long term follow-up indicates that a significant regression of improvement in visual 
function occurs(62).  
 
Treatment outcome 
Numerous studies have examined the visual acuity outcomes that can be achieved with 
treatment for amblyopia(7,23,63-67), however, this may diminish after treatment is 
completed.  A recent prospective study which monitored the level of visual acuity following 
the finalisation of treatment concluded that approximately a quarter of successfully treated 
amblyopic children experience a reduction in visual acuity within the first year of 
treatment(68). This recurrence rate was similar among patients who had previously been 
treated by patching and those who had been treated by penalisation with atropine and 
occurred more frequently during the first 13 weeks following commencement of treatment.  
Other studies have shown that about 2/3 of both strabismic and anisometropic amblyopes 
maintain, or even improve, visual acuity more than four years after treatment 
completed(69,70), however anisometropia of greater than 1.5 dioptres appears to be a risk 
factor for regression(71).The implication for clinical practice is that follow-up is warranted 
for at least 12 months following the completion of occlusion or penalisation treatment.  
Further randomised clinical trials are needed to investigate the long-term risk of amblyopia 
recurrence. 
 
Quality of binocular vision can also be used as an outcome indicator.  In a retrospective 
study of occlusion treatment outcomes, stereopsis was found to improve linearly with 
improved amblyopic visual acuity irrespective of the cause of amblyopia(72).  In 
comparison, in a large scale study of adults with amblyopia or with a history of risk factors 
for amblyopia, 90% of those who were believed to have had disruption of binocular vision 
during early visual development (ie those with a history of strabismus) failed tests of 
binocular function, even if visual acuity was within normal limits.  By comparison, 64% of 
adults with anisometropia and 35% of amblyopes with anisometropia passed these 
binocular tests(7).       
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Emotional Impact of Treatment  
Many parents of children undergoing occlusion treatment for amblyopia, even for relatively 
short periods of time, report distress or an increase in conflict at home.  Most parents 
associated occlusion with reduced confidence seen in their child due to poor vision under 
occlusion conditions(73).  Whilst not all parents report that their child’s activities are 
affected, the degree of compliance with treatment and observations of changes in patterns 
of behaviour has been found to differ depending on the level of amblyopia(74) .  No 
evidence of significant developmental delay or increased behavioural problems was found 
in a case-control study of congenital monocular cataract patients, who had their only 
normally seeing eye patched for a significant percentage of their early childhood years.  
However, the sample size was limited in this study and the use of siblings for the control 
group introduced the possibility of parental bias in their subjective assessment of the two 
children(75). 
 
It has now been shown in a randomised control trial of treatment that children undergoing 
occlusion patching were more upset and showed more resistance to their treatment than 
those prescribed glasses alone.  In addition, many parents experienced difficulty with 
occlusion therapy and were significantly more likely to be upset by this treatment than 
parents with children in glasses alone, however, the levels of distress and difficulty 
reported by parents were quite low(76).  This is in accord with a repeated measures study 
that recorded carer’s perception of stress and psychosocial well-being of the child prior to 
and following commencement of treatment.  Carers of children undergoing occlusion 
therapy did not experience significantly more stress or perceive their child as exhibiting 
less psychosocial well-being than the non-occluded group.  In addition, within the occluded 
group, carers’ stress level and child’s psychosocial well-being did not significantly change 
following onset of occlusion therapy(77).  Similarly, the PEDIG group found that both 
penalisation modalities, patch occlusion and atropine, were well tolerated by the child and 
family, although treatment impact scores were consistently worse in the occlusion group 
compared with the atropine group(78).   
  
Recent studies confirm that penalisation in amblyopia treatment creates negative changes 
in behaviour in many children and has an impact on family life.  These changes appear to 
be more profound in children with a greater level of amblyopia.  Whether this is due to 
greater visual impairment under penalised conditions or due to a longer duration of 
penalisation has not been established.  The behaviour of the child under penalisation 
conditions influences compliance with treatment, which raises the possibility that the 
efficacy of treatment could be reduced by poor compliance in those children with the 
greatest need. 
 
Functional Impact of Treatment 
While often cited as the reason for poor compliance with occlusion or penalisation, the 
ability to perform everyday tasks under monocular conditions with reduced visual acuity 
has not been documented in children with amblyopia.  Studies that have investigated 
performance on fine motor skills tasks under monocular versus binocular conditions 
suggest that performance would be impaired by the penalisation phase of amblyopia 
treatment due to loss of residual binocular vision.  It is likely that if amblyopic acuity is less 
than 6/12 then functional tasks would be further impaired.  However, there are a lack of 
studies specifically investigating functional disability in areas of importance to children of 
the age most likely to be treated for amblyopia.   Future studies need to address disability 
imposed by the treatment, especially performance under impaired monocular conditions 
imposed by penalisation.  Also, once a child has been dismissed from amblyopia treatment 
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they may still have some visual function anomaly such as reduced stereopsis, abnormal 
accommodation or poor ocular-motor function.  The impact of these binocular vision 
anomalies on tasks important to children warrants investigation. 
 
Costs of Treatment 
The medical costs associated with amblyopia treatment can be calculated based on 
estimates of consultation fees, non-surgical and surgical fees.  Specific costs in nominal 
US dollars in 2001 varied between $1452 and $2628 (dependant upon surgical or non-
surgical treatment of the underlying cause) and averaged $1623 per patient(34).  This 
same study weighed the cost of amblyopia treatment against quality of life utility value 
gained due to improved visual acuity in the amblyopic eye and concluded that amblyopia 
therapy is particularly cost-effective to a large degree because the visual acuity benefit 
derived is acquired at a very young age. 
 
Compliance with Treatment 
Compliance with occlusion treatment is essential for an optimum outcome and has been 
the subject of numerous studies (79-82).  The level of compliance to treatment has been 
shown to be influenced by patient age(80,81), social deprivation(82), level of visual 
acuity(81), parental understanding of the condition and treatment(83) as well as by the 
financial and emotional cost to patient and family(76,84,85). Strategies used to enforce 
patch wear include encouraging, ordering, pleading, threatening, bribery, hospital 
administration, arm restraint by use of plaster cast and eye lid suturing (79,86).  Beardsall 
et al (87) found that most parents of children with amblyopia were highly motivated to 
undertake recommended treatment after becoming aware of the reduced visual acuity at 
the initial vision examination.  As non-compliance with treatment sometimes delayed 
effective treatment, Beardsall et al (87) suggest an occlusion protocol aimed at giving 
maximum support for parents in the early stages of treatment.  This was supported by 
Searle et al(85) who found parental compliance improved if they believed treatment was 
producing positive results and decreased if there was perceived restriction of the child’s 
activities by patching.   Similarly, it has been suggested that increased parental awareness 
of the rationale and urgency of occlusion treatment, with reinforcement of details of the 
regimen, would help to reduce non-compliance(83).  This has been tested in a randomised 
controlled trial of written information which concluded that a large proportion of patients 
would benefit by increasing parental knowledge in key areas such as the critical period, 
importance of occlusion and potential negative consequences of not treating amblyopia 
(88). Low socio-economic status, measured by qualification for Medicaid assistance, has 
been reported to indicate reduced likelihood for success for amblyopia therapy.  Patients 
whose family qualified for Medicaid assistance (n=71) had poorer final visual acuity, greater 
number of missed visits and lower estimate of compliance than those whose families did 
not qualify for Medicaid (n=209) (28).   
 
Summary  
Recent randomised controlled trials of treatment for amblyopia and early screening and 
treatment studies have provided evidence regarding the natural history of amblyopia and 
efficacy of treatment.  These studies indicate that treatment of amblyopia reduces the 
incidence of amblyopia and results in better final visual acuity in the amblyopic eye.  
Studies have also indicated that the earlier amblyogenic factors are detected and treated, 
the lower the prevalence and severity of amblyopia.  In the context of overall outcomes for 
the population, it can be concluded that the results justify the treatment.  Occlusion or 
penalisation in amblyopia treatment can create negative changes in behaviour in children 
and have an impact on family life, more so in children with greater level of amblyopia.  As 
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the child’s behaviour influences compliance, it is essential to address this issue with the 
parent supervising the treatment when instigating the occlusion or penalisation therapy. 
Allowing refractive adaptation prior to commencement of occlusion or penalisation therapy 
may have significant benefits for the child such as starting occlusion or penalisation with 
improved visual acuity, possibly enhancing compliance, and in some cases unnecessary 
patching will be avoided.  
 
Reports of disability for the patient with amblyopia are not conclusive and do not 
specifically address skills that are of importance to the childhood population.  Whilst the 
balance between possible disabilities attributable to the condition versus the treatment has 
not been established, the potential disability of incapacitating vision loss later in life, due to 
loss of visual function of the non-amblyopic eye, can be calculated and is an argument for 
treatment to maximise visual potential in each eye 
 
The studies of PEDIG have provided clinicians with more distinct guidelines with respect to 
the “how” and “when” of occlusion and penalisation therapy in amblyopia.  Randomised 
treatment trials in child and adolescent age groups older than what has traditionally been 
considered the critical period within which treatment is effective are currently ongoing.  
Similarly, the outcome of ongoing randomised treatment trials examining the influence of 
near activity during patching will provide direction to “active” versus “passive” patching.  
The importance of parental education and support to maximise compliance with treatment 
has now been established and should be part of the treatment plan(88).   
 
Importantly, this review highlights the need for evidence-based guidelines for treatment of 
amblyopia to be developed so that clinicians can provide optimal advice and treatment for 
amblyopia with minimal impact for the patient. It also highlights the amount of recent 
research activity in this area and the need for clinicians to keep up to date with recent 
literature in order to provide the best level of care for their amblyopic patients that current 
knowledge allows.  
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Populations Percentage 
Recruited soldiers  
Irvine* 1.0 
Helveston* 1.0 
Theodore et. al.* 1.4 
Evens and Kuypers* 1.8 
Glover and Brewster* 2.4 
Downing* 3.2 
  
Preschool and school-age children  
Friedman et. al. * 0.5 
Russell et. al. * 1.3 
DaCunha and Jenkins* 1.7 
Flom and Neumaier* 1.8 
McNeil* 2.7 
Frandsen* 3.1 
Vereecken et. al.* 3.5 
Thompson et. al.(4) 3.0 
ALSPAC – early screening(18) 1.1 
ALSPAC – late screening(18) 2.0 
Eibschitz-Tsimhoni et al(19) – early 
screening 
1.0 
Eibschitz-Tsimhoni et al(19) – late 
screening 
2.6 
  
  
Older population  
Vinding et. al. * 2.9 
Brown et. al.(15) 
Attebo et al (3) 
3.06 
3.2 
  
Ophthalmic patients  
Irvine* 4.0 
De Roeth* 4.5 
Cole* 5.3 
  
TABLE 1: Reported Prevalence of amblyopia in selected populations 
*From Von Noorden(1) with recent studies by Thompson(4), Attebo et al (3), Brown et 
al(15), ALSPAC(18) and Eibschitz-Tsimhoni et al(19) added into table  
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